Viewing Study NCT06862869


Ignite Creation Date: 2025-12-24 @ 11:13 PM
Ignite Modification Date: 2025-12-25 @ 8:48 PM
Study NCT ID: NCT06862869
Status: RECRUITING
Last Update Posted: 2025-12-12
First Post: 2025-02-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module